SCHEMBL4056443

SCHEMBL4056443

COc1ccc(OC)c(Cc2nc3ncc(-c4ccccc4F)cc3[nH]2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.51
HSP90AB1 P08238 1/20 0.51
NOS1 P29475 4/20 0.47
NOS2 P35228 4/20 0.47
NOS3 P29474 3/20 0.47
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
LMNA P02545 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
ALDH1A1 P00352 1/20 0.41
MDM2 Q00987 1/20 0.41
DHFR P00374 2/20 0.40
SCD O00767 1/20 0.40
TEK Q02763 1/20 0.39
AURKA O14965 1/20 0.37
PDE2A O00408 1/20 0.37
ALOX5AP P20292 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4052000 0.87 NOS1 (0.61) HSP90AA1HSP90AB1NOS1NOS2NOS3
SCHEMBL4051128 0.86 NOS3 (0.48) NOS1NOS2NOS3NPC1RAB9A
SCHEMBL13607961 0.84 HSP90AB1 (0.46) HSP90AA1HSP90AB1NPC1RAB9ASMN1; SMN2
SCHEMBL4051456 0.84 POLB (0.55) NOS1NOS2NOS3NPC1RAB9A
SCHEMBL4062462 0.84 NOS3 (0.48) NOS1NOS2NOS3NPC1RAB9A
SCHEMBL4049571 0.83 POLB (0.46) NOS1NOS2NOS3LMNAHTT
SCHEMBL4062382 0.80 NOS1 (0.47) HSP90AA1HSP90AB1NOS1NOS2NOS3
SCHEMBL4054995 0.80 HSP90AA1 (0.48) HSP90AA1HSP90AB1NOS1NOS2NOS3
SCHEMBL4057239 0.79 SMN1; SMN2 (0.61) HSP90AA1HSP90AB1NOS1NOS2NOS3
SCHEMBL4052646 0.78 SCD (0.45) NOS1NOS2NOS3NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B HSP90AA1 3577/4885HSP90AB1 1989/4885NOS1 879/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.